Glycoprotein IIb/IIIa inhibitors.
The GPIIb/IIIa inhibitors are potent anti-platelet agents with proven benefits in the treatment of patients with acute coronary syndromes and/or undergoing PCI. Assessment of the balance of risk and benefit needs to be undertaken in each individual case Consideration needs to be given to the economic impact of using these expensive drugs. There is much research activity in this rapidly evolving field and clinical experience is continually growing.
Stevens
Mel
M
St George's Hospital, Tooting, London, UK.
D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000077542:Eptifibatide; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D010455:Peptides / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D000077466:Tirofiban; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014443:Tyrosine; D000077466:Tirofiban; D000077542:Eptifibatide; D000077284:Abciximab